2024
Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications
Rashedi S, Greason C, Sadeghipour P, Talasaz A, O'Donoghue M, Jimenez D, Monreal M, Anderson C, Elkind M, Kreuziger L, Lang I, Goldhaber S, Konstantinides S, Piazza G, Krumholz H, Braunwald E, Bikdeli B. Fibrinolytic Agents in Thromboembolic Diseases: Historical Perspectives and Approved Indications. Seminars In Thrombosis And Hemostasis 2024, 50: 773-789. PMID: 38428841, DOI: 10.1055/s-0044-1781451.Peer-Reviewed Original ResearchST-segment elevation myocardial infarctionTissue plasminogen activatorFood and Drug AdministrationFibrinolytic agentsThromboembolic diseasePlasminogen activatorFood and Drug Administration approvalArterial thromboembolic eventsElevation myocardial infarctionCentral venous access device occlusionPlasma half-lifeU.S. Food and Drug AdministrationAcute ischemic strokePulmonary embolismThromboembolic eventsHemodynamic compromiseDevice occlusionTreated patientsRecanalize occluded vesselsActive protease plasminDrug AdministrationMyocardial infarctionApproved indicationsOccluded vesselIschemic stroke
1995
A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction
Kalish S, Gurwitz J, Krumholz H, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. Journal Of General Internal Medicine 1995, 10: 321-330. PMID: 7562123, DOI: 10.1007/bf02599951.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsTissue plasminogen activatorAcute myocardial infarctionAdditional quality-adjusted life yearMyocardial infarctionGUSTO trialThrombolytic therapyOne-year mortality dataOccluded Coronary Arteries (GUSTO-I) trialMortality dataPlasminogen activatorLong-term medical costsCoronary Arteries trialOne-year mortalityUse of streptokinaseInferior wall infarctionCost-effective therapyCost-effectiveness modelDecision analysis modelSurvival benefitSymptom onsetClinical outcomesRelative survival advantageThrombolytic agentsSurvival advantage